8FO8
Cryo-EM structure of Rab29-LRRK2 complex in the LRRK2 dimer state
Summary for 8FO8
| Entry DOI | 10.2210/pdb8fo8/pdb |
| EMDB information | 29341 |
| Descriptor | Ras-related protein Rab-7L1, Leucine-rich repeat serine/threonine-protein kinase 2, GUANOSINE-5'-DIPHOSPHATE, ... (4 entities in total) |
| Functional Keywords | cryo-em, parkinson's disease, kinase, lrrk2, rab gtpases, activation, hydrolase |
| Biological source | Homo sapiens (human) More |
| Total number of polymer chains | 4 |
| Total formula weight | 615234.23 |
| Authors | |
| Primary citation | Zhu, H.,Tonelli, F.,Turk, M.,Prescott, A.,Alessi, D.R.,Sun, J. Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2. Science, 382:1404-1411, 2023 Cited by PubMed Abstract: Gain-of-function mutations in , which encodes the leucine-rich repeat kinase 2 (LRRK2), are the most common genetic cause of late-onset Parkinson's disease. LRRK2 is recruited to membrane organelles and activated by Rab29, a Rab guanosine triphosphatase encoded in the locus. We present cryo-electron microscopy structures of Rab29-LRRK2 complexes in three oligomeric states, providing key snapshots during LRRK2 recruitment and activation. Rab29 induces an unexpected tetrameric assembly of LRRK2, formed by two kinase-active central protomers and two kinase-inactive peripheral protomers. The central protomers resemble the active-like state trapped by the type I kinase inhibitor DNL201, a compound that underwent a phase 1 clinical trial. Our work reveals the structural mechanism of LRRK2 spatial regulation and provides insights into LRRK2 inhibitor design for Parkinson's disease treatment. PubMed: 38127736DOI: 10.1126/science.adi9926 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.88 Å) |
Structure validation
Download full validation report
